Researchers from the Office of Clinical Evaluation of Biological Products, Center for Drug Evaluation, China Food and Drug Administration recently produced a report titled “The Landscape of Car T-cell Therapy in the United States and China: A comparative analysis,” published in the International Journal of Cancer.
China has rapidly emerged as a viable center of novel innovation in cancer research and development. Three of the four authors work for the Chinese regulatory authority and hence posses a strategic perspective on the emergence of this new class of treatment as it unfolds in both critically important countries.
Introduction to the Research
They note that clinical trials of CAR T-cell therapy are rapidly growing in both the United States and China. They emphasize that exhibiting the distinctions between the clinical trials in the two countries is of great value for understanding the panorama of CAR T-cell clinical trials and forecasting the future of this promising therapy.
The authors analyzed the critical elements of 289 clinical trials posted on the Clinicaltrials.gov website by sponsors from the two countries—they evaluated the efficacy data in the availabl...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).